[go: up one dir, main page]

PL3377500T3 - Związki oksadiazaspiro do leczenia nadużywania i uzależnienia od narkotyków/leków - Google Patents

Związki oksadiazaspiro do leczenia nadużywania i uzależnienia od narkotyków/leków

Info

Publication number
PL3377500T3
PL3377500T3 PL16797458.3T PL16797458T PL3377500T3 PL 3377500 T3 PL3377500 T3 PL 3377500T3 PL 16797458 T PL16797458 T PL 16797458T PL 3377500 T3 PL3377500 T3 PL 3377500T3
Authority
PL
Poland
Prior art keywords
drug
dependence
treatment
abuse
oxadiazaspiro
Prior art date
Application number
PL16797458.3T
Other languages
English (en)
Inventor
Marina VIRGILI-BERNADO
Carmen ALMANSA-ROSALES
Carlos ALEGRET-MOLINA
Original Assignee
Esteve Pharmaceuticals, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals, S.A. filed Critical Esteve Pharmaceuticals, S.A.
Publication of PL3377500T3 publication Critical patent/PL3377500T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
PL16797458.3T 2015-11-16 2016-11-15 Związki oksadiazaspiro do leczenia nadużywania i uzależnienia od narkotyków/leków PL3377500T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382566 2015-11-16
PCT/EP2016/001907 WO2017084752A1 (en) 2015-11-16 2016-11-15 Oxadiazaspiro compounds for the treatment of drug abuse and addiction

Publications (1)

Publication Number Publication Date
PL3377500T3 true PL3377500T3 (pl) 2023-01-23

Family

ID=54707728

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16797458.3T PL3377500T3 (pl) 2015-11-16 2016-11-15 Związki oksadiazaspiro do leczenia nadużywania i uzależnienia od narkotyków/leków

Country Status (30)

Country Link
US (2) US10927128B2 (pl)
EP (1) EP3377500B1 (pl)
JP (1) JP6884974B2 (pl)
KR (2) KR20180080327A (pl)
CN (1) CN108349999A (pl)
AR (1) AR106697A1 (pl)
AU (1) AU2016356488B2 (pl)
CA (1) CA3002286A1 (pl)
CO (1) CO2018004665A2 (pl)
DK (1) DK3377500T3 (pl)
ES (1) ES2932000T3 (pl)
HR (1) HRP20221343T1 (pl)
HU (1) HUE060275T2 (pl)
IL (1) IL259035B (pl)
LT (1) LT3377500T (pl)
MA (1) MA43250B1 (pl)
MX (1) MX384637B (pl)
MY (1) MY193423A (pl)
PH (1) PH12018500814A1 (pl)
PL (1) PL3377500T3 (pl)
PT (1) PT3377500T (pl)
RS (1) RS63734B1 (pl)
SG (1) SG11201803153RA (pl)
SI (1) SI3377500T1 (pl)
SM (1) SMT202200460T1 (pl)
TN (1) TN2018000122A1 (pl)
TW (1) TWI756196B (pl)
UA (1) UA123775C2 (pl)
WO (1) WO2017084752A1 (pl)
ZA (1) ZA201802845B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE060275T2 (hu) 2015-11-16 2023-02-28 Esteve Pharmaceuticals Sa Hatóanyaggal való visszaélés és addikció kezelésére alkalmas oxadiazaspiro-vegyületek
WO2020157026A1 (en) * 2019-01-28 2020-08-06 Esteve Pharmaceuticals, S.A. Hydroxylated derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
US20250002503A1 (en) 2021-09-20 2025-01-02 Esteve Pharmaceuticals, S.A. Oxadiazaspiro compounds for use in the treatment of motoneuron degeneration or in neuroprotection
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244961A (en) * 1978-10-26 1981-01-13 Syntex (U.S.A.) Inc. 1-Oxa-3,8-diazaspiro[4.5]decan-2-ones antihypertensive agents
US4332804A (en) 1981-03-23 1982-06-01 Syntex (U.S.A.) Inc. 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353901A (en) * 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353900A (en) 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
US6114541A (en) 1997-03-10 2000-09-05 Hoffmann-La Roche Inc. Method for the preparation of α-Bromo-Lactam derivatives
AU2005211499A1 (en) * 2004-02-10 2005-08-18 F. Hoffmann-La Roche Ag Chemokine CCR5 receptor modulators
DE602005025979D1 (de) 2004-03-03 2011-03-03 Vital Health Sciences Pty Ltd Alkaloid-formulierungen
EP1634873A1 (en) 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
US7951816B2 (en) * 2004-08-27 2011-05-31 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
CN101228127B (zh) 2005-05-30 2012-05-16 Msdk.K.公司 哌啶衍生物
CN101203567A (zh) * 2005-06-07 2008-06-18 西巴特殊化学品控股有限公司 抗刮擦聚烯烃
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
CN103382176A (zh) 2005-10-19 2013-11-06 格吕伦塔尔有限公司 新颖的辣椒素受体配体和它们用于生产药物的用途
PL1961744T3 (pl) 2005-11-18 2013-09-30 Ono Pharmaceutical Co Związek zawierający grupę zasadową oraz jego zastosowanie
EP1829869A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. 4,5,6,7-Tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands
EP1847542A1 (en) 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
US8877779B2 (en) 2007-03-01 2014-11-04 Mitsubishi Tanabe Pharma Corporation Benzimidazole compound and pharmaceutical use thereof
EP1982714A1 (en) 2007-04-16 2008-10-22 Laboratorios del Dr. Esteve S.A. Pyrano-pyrazole-amines
EP2020414A1 (en) * 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
EP2197876A1 (en) 2007-08-29 2010-06-23 Glaxosmithkline LLC Thiazole and oxazole kinase inhibitors
EP2070933A1 (en) 2007-12-07 2009-06-17 Laboratorios del Dr. Esteve S.A. Tricyclic triazolic compounds
PL2242759T3 (pl) 2008-02-06 2013-06-28 Astrazeneca Ab Związki
EP2108643A1 (en) * 2008-04-10 2009-10-14 Laboratorios Del. Dr. Esteve, S.A. 4-methyl-4, 5-dihydro-1H-pyrazole-3-carboxamide useful as a cannabinoid CB1 neutral antagonist
GB201016912D0 (en) * 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
EP2686325B1 (en) 2011-03-14 2016-12-14 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
GB201107985D0 (en) 2011-05-13 2011-06-29 Astrazeneca Ab Process
WO2013052716A1 (en) * 2011-10-07 2013-04-11 Glaxosmithkline Llc Fatty acid synthase inhibitors
WO2013115294A1 (ja) * 2012-01-31 2013-08-08 東レ株式会社 ジアザスピロウレア誘導体及びその医薬用途
EP3027625B1 (en) 2013-07-31 2018-05-30 Merck Sharp & Dohme Corp. Spiro-fused derivatives of piperidine useful for the treatment of inter alia hypertension and acute or chronic heart failure
TW201615642A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性的１－氧雜－４，９－二氮雜螺十一烷化合物之醯胺衍生物
TWI685497B (zh) * 2014-06-02 2020-02-21 西班牙商伊史帝夫製藥公司 具有多重模式抗疼痛活性的１-氧雜-４,９-二氮雜螺十一烷化合物之烷基衍生物
TW201615643A (zh) * 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物
US10513518B2 (en) * 2015-01-29 2019-12-24 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
HUE060275T2 (hu) 2015-11-16 2023-02-28 Esteve Pharmaceuticals Sa Hatóanyaggal való visszaélés és addikció kezelésére alkalmas oxadiazaspiro-vegyületek

Also Published As

Publication number Publication date
US20180327422A1 (en) 2018-11-15
MA43250B1 (fr) 2022-12-30
RU2018120748A (ru) 2019-12-05
JP2018533598A (ja) 2018-11-15
WO2017084752A1 (en) 2017-05-26
DK3377500T3 (da) 2022-11-21
BR112018009279A2 (pt) 2018-11-06
EP3377500B1 (en) 2022-10-19
MY193423A (en) 2022-10-12
RU2018120748A3 (pl) 2020-02-07
KR20250069710A (ko) 2025-05-19
RS63734B1 (sr) 2022-12-30
CA3002286A1 (en) 2017-05-26
ES2932000T3 (es) 2023-01-09
AR106697A1 (es) 2018-02-07
SI3377500T1 (sl) 2023-02-28
US20210115062A1 (en) 2021-04-22
PH12018500814A1 (en) 2018-10-29
IL259035B (en) 2021-06-30
PT3377500T (pt) 2022-11-25
MA43250A (fr) 2021-04-14
BR112018009279A8 (pt) 2019-02-26
EP3377500A1 (en) 2018-09-26
SG11201803153RA (en) 2018-06-28
HUE060275T2 (hu) 2023-02-28
HRP20221343T1 (hr) 2022-12-23
SMT202200460T1 (it) 2023-01-13
AU2016356488B2 (en) 2020-10-22
TWI756196B (zh) 2022-03-01
IL259035A (en) 2018-06-28
JP6884974B2 (ja) 2021-06-09
CO2018004665A2 (es) 2018-07-19
MX2018005439A (es) 2018-11-09
MX384637B (es) 2025-03-14
US11649248B2 (en) 2023-05-16
TN2018000122A1 (en) 2019-10-04
KR20180080327A (ko) 2018-07-11
US10927128B2 (en) 2021-02-23
CN108349999A (zh) 2018-07-31
UA123775C2 (uk) 2021-06-02
LT3377500T (lt) 2022-12-12
TW201731854A (zh) 2017-09-16
AU2016356488A1 (en) 2018-05-10
ZA201802845B (en) 2021-10-27

Similar Documents

Publication Publication Date Title
IL272820A (en) History of sulfamolepyrolamide and their use as hepatitis B drugs
IL259441A (en) Materials and methods for treatment of titin-based myopathies and other titinopaties
EP3302442C0 (en) DOSAGE FORMS AND THEIR USE
EP4212536C0 (en) BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE
PL3265053T3 (pl) Sposoby leczenia skóry
LT3206715T (lt) Kanabidiolio naudojimas tuberozinės sklerozės komplekso gydymui
LT3283527T (lt) Kompleksinė terapija vėžio gydymui
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
IL254552A0 (en) Polycyclic carbamoylpyridone compounds and their pharmaceutical uses
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
HUE055263T2 (hu) 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére
HUE049413T2 (hu) Nazális porkészítmény hipoglikémia kezelésére
DK3328864T3 (da) Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser
LT3297653T (lt) Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais
IL256103B (en) Compositions and methods for treating celiac sprue disease
GB201617064D0 (en) Compounds and their therapeutic use
IL251404A0 (en) Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
DK3302478T3 (da) Pac-1 kombinations behandling
ZA201802134B (en) Therapeutic compounds and methods of use thereof
PL3373922T3 (pl) Kompozycje i sposoby do stosowania do leczenia homocystynurii
PL3377500T3 (pl) Związki oksadiazaspiro do leczenia nadużywania i uzależnienia od narkotyków/leków
PL3203998T3 (pl) Podstawione związki aromatyczne i kompozycje farmaceutyczne do zapobiegania i leczenia cukrzycy
DK3395350T3 (da) Lægemiddel til behandling af hjerneinfarkt
PL3377061T3 (pl) Mirabegron do leczenia chorób siatkówki
TH1601002131A (th) สารอนุพันธ์คาร์บอกซามีค เเละการใช้ของสิ่งนั้นเป็นยาสำหรับการบำบัดตับอักเสบ b